---
title: "002422.SZ (002422.SZ) — 相关新闻"
type: "Symbol"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/quote/002422.SZ/news.md"
symbol: "002422.SZ"
name: "002422.SZ"
parent: "https://longbridge.com/zh-CN/quote/002422.SZ.md"
datetime: "2026-03-14T10:34:35.729Z"
locales:
  - [en](https://longbridge.com/en/quote/002422.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002422.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002422.SZ/news.md)
---

> 支持的语言: [English](https://longbridge.com/en/quote/002422.SZ/news.md) | [繁體中文](https://longbridge.com/zh-HK/quote/002422.SZ/news.md)


# 002422.SZ (002422.SZ) — 相关新闻

### [Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results](https://longbridge.com/zh-CN/news/278713493.md)
*2026-03-11T11:40:25.000Z*
> Kelun-Biotech Sets March 2026 Board Meeting and Webcast for 2025 Results

### [KELUN PHARMA's subsidiary new drug SKB575 approved for clinical use, partnering with HBM HOLDINGS to tackle the treatment challenges of atopic dermatitis](https://longbridge.com/zh-CN/news/278673316.md)
*2026-03-11T07:17:18.000Z*
> KELUN PHARMA's subsidiary Sichuan KELUN BIO-TECH has collaborated with HBM HOLDINGS-B to develop the bispecific antibody

### [Sichuan Kelun-Biotech Hires Associate For Promotional Services of Drug](https://longbridge.com/zh-CN/news/278650252.md)
*2026-03-11T03:18:16.000Z*
> Sichuan Kelun-Biotech Hires Associate For Promotional Services of Drug

### [06:47 ETKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Atopic Dermatitis](https://longbridge.com/zh-CN/news/278376120.md)
*2026-03-09T10:48:57.000Z*
> Sichuan Kelun-Biotech and Harbour BioMed announced that the National Medical Products Administration (NMPA) of China has

### [Danna Biotech: The company's fundraising projects include the headquarters base construction project and new product research and development projects](https://longbridge.com/zh-CN/news/278375494.md)
*2026-03-09T10:44:42.000Z*
> Danna Biotech released an investor relations activity record on March 9, announcing that its fundraising projects includ

### [Sichuan Kelun-Biotech Secures Regulatory Approval to Begin Human Trials of Dermatology Drug](https://longbridge.com/zh-CN/news/278371431.md)
*2026-03-09T10:20:54.000Z*
> Sichuan Kelun-Biotech Secures Regulatory Approval to Begin Human Trials of Dermatology Drug

### [HBM HOLDINGS-B: The clinical trial application for the new drug HBM7575 for the treatment of atopic dermatitis has been approved by the NMPA](https://longbridge.com/zh-CN/news/278356176.md)
*2026-03-09T08:34:19.000Z*
> HBM HOLDINGS-B announced that its new drug clinical trial application for the long-acting bispecific antibody HBM7575 (a

### ["Extraordinary Argument - Wen Qiao Fei" has great overseas potential, electric stocks continue to rise, JD.com and Aobo are about to announce their earnings](https://longbridge.com/zh-CN/news/277890085.md)
*2026-03-05T06:36:00.000Z*
> According to the report from "Feichang Lunzheng," market risk aversion sentiment has slightly decreased, U.S. stocks hav